Both Doudna and Bertozzi, even before their recognition by Nobel Prize committees, are helping a new generation of Bay Area biotech entrepreneurs. At the same time, their innovations — Doudna’s CRISPR genome-editing technology and Bertozzi’s bioorthogonal chemistry — are evolving from tools in scientists’ labs to the power behind a range of potential drug treatments and cures.
